Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors trying to untangle Spyre Therapeutics’ biotech disclosures often wade through pages of immunology jargon, multi-year R&D accruals, and milestone-based licensing clauses. Locating clinical-trial costs in a 10-K or confirming a sudden Form 8-K study halt can take hours, and tracking executive share sales before financing rounds is even harder. That complexity is why so many searches start with natural questions like “where can I find Spyre Therapeutics quarterly earnings report 10-Q filing?” or “Spyre Therapeutics insider trading Form 4 transactions.” We built this page to answer those questions immediately.
With Stock Titan’s AI-powered analysis, every Spyre Therapeutics SEC filing is explained simply. Our algorithms parse the latest 10-K annual report, highlight key pipeline disclosures, and surface cash-burn trends, giving you a “Spyre Therapeutics annual report 10-K simplified” view in seconds. Real-time alerts flag “Spyre Therapeutics Form 4 insider transactions” the moment they hit EDGAR, while concise summaries break down each “Spyre Therapeutics 8-K material events explained” notice. Whether you need “Spyre Therapeutics proxy statement executive compensation” tables, or an “earnings report filing analysis” of quarterly R&D spend, the information arrives ready to use.
Every filing is linked to what matters for this clinical-stage IBD innovator. Compare α4β7 antibody trial results across quarters, monitor financing covenants that could shift run-way projections, or study “understanding Spyre Therapeutics SEC documents with AI” case notes that connect pipeline milestones to market valuation. Our coverage spans all forms—10-K, 10-Q, 8-K, S-1, and the executive stock transactions Form 4 feed—updated in real time. Spend less time decoding dense biology and more time making informed decisions with complete, investor-ready context.
The Vanguard Group filed Amendment No. 15 to Schedule 13G on Summit Hotel Properties (INN) covering holdings as of 30 Jun 2025.
- Beneficial ownership: 13,178,484 common shares, equal to 11.74 % of shares outstanding.
- Voting power: 0 sole; 69,079 shared—Vanguard exercises very limited voting authority.
- Dispositive power: 13,006,838 sole; 171,646 shared.
- Filed under Rule 13d-1(b) as an investment adviser (IA); securities held in the ordinary course for client accounts.
- Certification signed by Ashley Grim, Head of Global Fund Administration, on 29 Jul 2025.
The filing confirms Vanguard remains a major passive holder of INN. While the 11.74 % stake provides market influence, the near-zero voting power limits its ability to sway corporate governance directly.